Volume of distribution (L/kg)       :No data
half-life – normal/ESRD (hrs)      :No data
DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50     : 4 g daily
10 to 20     : 2–4 g daily
<10           : 2–4 g daily
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Not dialysed. Dose as in GFR <10 mL/min
HD                     :Not dialysed. Dose as in GFR <10 mL/min
HDF/high flux   :Unknown dialysability. Dose as in GFR <10 mL/min
CAV/VVHD      :Not dialysed. Dose as in GFR=10–20 mL/min
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugsReduced absorption of digoxin, tetracyclines, quinolones, coumarins and phenytoin – give 2 hours after sucralfate
ADMINISTRATION
Reconstition
–
Route
Oral
Rate of Administration
–
Comments
Sucralfate exerts its action at the site of the ulcer, and is minimally absorbed (3–5%) from the GI tract as sucrose sulphateIn normal renal function, any aluminium which is absorbed is excreted in the urineTablets may be dispersed in 10–15 mL of water
OTHER INFORMATION
Sucralfate should be used with caution in renal impairment as aluminium may be absorbed and accumulateIn severe renal impairment and patients receiving dialysis, sucralfate should be used with extreme caution and only for short periodsAbsorbed aluminium is bound to plasma proteins and is not dialysableUse of other aluminium-containing products with sucralfate can increase the total body burden of aluminium